A Retrospective Study in Outcome of Patients with Colon Cancer and Chronic Viral Hepatitis Treated with Chemotherapy

化學治療結腸癌與慢性病毒性肝炎之回顧性研究

方川尹(Chuan-Yin Fang) ； 陳啟益(Chi-Yi Chen) ； 林怡成(I-Chen Lin) ； 張育茹(Yu-Ju Chang) ； 李明陽(Ming-Yang Lee)

《南臺灣醫學雜誌》 14卷1期 (2018/06) Pp. 13-20

https://doi.org/10.6726/MJST.201806_14(1).0002

摘要

Objective: In some cancers, patients with viral hepatitis B or C infections have more chemotherapy-related morbidity and mortalities. Methods: Patients' characteristics, included age, gender, stage were similar between patients with chronic viral hepatitis and without hepatitis. Median survival was 1292 days (95% CI, 518-2065 days) in patients with chronic viral hepatitis and 1228 days (95% CI, 968-1487 days) in patient without chronic hepatitis. There were no significant overall survival differences in these two groups (p = 0.793). In subgroup analysis, there were still no survival differences between different stages. Results: Patients who were ≤ 65 years (p ＜ 0.001) and had lower normal urine albumin creatinine ratio (ACR, p = 0.049) had lower chance to become albuminuria. Hypertension (p = 0.021), albuminuria (p = 0.022) and age ＞ 65 years (p = 0.04) would deteriorate renal function but patients under angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) therapy were exceptional. Conclusions: Chronic hepatitis B or C infections did not influence survival in colon cancer patients treated with chemotherapy.

關鍵字

chemotherapy ； colon cancer ； hepatitis B ； hepatitis C ； survival.

並列摘要

目的：全身化學治療提供結腸癌I I期、I I I期與I V期患者的生存優勢。在一些癌症患者中，如合併感染病毒性B型肝炎或C型肝炎，有更高和化學治療相關的發病率與死亡率。方法：本回顧性研究調查2007年1月至2011年12月在一個機構的568例結腸癌患者接受化療治療結腸癌。分析患者的特點、疾病分期、化學治療方式、肝炎感染狀況與總生存期。結果：結腸癌患者有無同時罹患慢性病毒性肝炎，在年齡、性別、分期等結果相似。有慢性病毒性肝炎患者的中位生存期為1292天(95%CI，518-2065天)，無慢性肝炎患者的中位生存期為1228天 (95%CI，968-1487天)，這兩組中總生存沒有顯著差異(p = 0.793)；不同階段間仍然沒有生存差異。結論：罹患慢性B型肝炎或C型肝炎之感染不影響化學治療結腸癌患者的存活。

並列關鍵字

化學治療 ； 結腸癌 ； B型肝炎 ； C型肝炎 ； 存活